71605-72-6

Basic information

• Product Name: 2,1,3-Benzothiadiazole-5-carbaldehyde
• Synonyms: BUTTPARK 75\50-32;2,1,3-BENZOTHIADIAZOLE-5-CARBALDEHYDE;2,1,3-BENZOTHIADIAZOLE-5-CARBOXALDEHYDE;Benzo[1,2,5]thiadiazole-5-carbaldehyde;benzo[c][1,2,5]thiadiazole-5-carbaldehyde;2,1,3-benzothiadiazole-5-carbaldehyde(SALTDATA: FREE);5-ForMyl-2,1,3-benzothiadiazole;2,1,3-benzothiadiazole-6-carbaldehyde
• CAS NO: 71605-72-6
• Molecular Formula: C₇H₄N₂OS
• Molecular Weight: 164.18
• Mol File: 71605-72-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 90 °C
• Boiling Point: 291.9 °C at 760 mmHg
• Flash Point: 130.3 °C
• Appearance: /
• Density: 1.477 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.753
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.78±0.36(Predicted)
• CAS DataBase Reference: 2,1,3-Benzothiadiazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,1,3-Benzothiadiazole-5-carbaldehyde(71605-72-6)
• EPA Substance Registry System: 2,1,3-Benzothiadiazole-5-carbaldehyde(71605-72-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41-37/38
• Safety Statements: 26-36/37/39-24/25-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 71605-72-6(Hazardous Substances Data)

Usage

General Description

2,1,3-Benzothiadiazole-5-carbaldehyde is a chemical compound with the molecular formula C8H5NOS. It is a heterocyclic aromatic organic compound that contains a benzene ring fused to a thiadiazole ring. This chemical is a yellow solid that is commonly used as a building block in organic synthesis and in the production of pharmaceuticals, dyes, and agrochemicals. It has also been studied for its potential use in organic electronic devices, such as organic light-emitting diodes (OLEDs) and organic photovoltaic cells, due to its strong electron-accepting properties and high electron mobility. Additionally, 2,1,3-Benzothiadiazole-5-carbaldehyde has been found to exhibit bioactive properties, with potential applications in the development of new drugs and biologically active compounds.

InChI:InChI=1/C7H4N2OS/c10-4-5-1-2-7-6(3-5)8-9-11-7/h1-4H

Upstream product

• 175204-21-4 methyl benzo-2,1,3-thiadiazole-5-carboxylate 
• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 619-05-6 3,4-diaminobenzoic acid 
• 65858-50-6 5-bromomethyl-benzo[1,2,5]thiadiazole 
• 1457-93-8 5-methylbenzo[c][1,2,5]thiadiazole 
• 89795-51-7 2,1,3-benzothiadiazol-5-ylmethanol 
• 71605-71-5 N'-benzo[1,2,5]thiadiazol-5-ylmethylene-N,N-dimethyl-benzene-1,4-diamine N'-oxide 

Downstream Products

• 16405-98-4 benzo[c][1,2,5]thiadiazole-5-carboxylic acid 
• 71605-70-4 5-thiazolidin-2-yl-benzo[1,2,5]thiadiazole 
• 89795-51-7 2,1,3-benzothiadiazol-5-ylmethanol 
• 364050-15-7 1-(benzo[c] [1,2,5]thiadiazol-5-yl)-2-(6-methylpyridin-2-yl)ethane-1,2-dione 
• 949465-70-7 2-(2-bromo-phenylamino)-5-(3,4-diamino-benzylidene)-thiazol-4-one 
• 1367578-55-9 5-(benzo[c][1,2,5]thiadiazol-5-ylmethylene)-3-benzyl-2-thioxothiazolidin-4-one 
• 1018814-89-5 (6R,12aR)-6-benzo[1.2.5]thiadiazol-5-yl-2-((R)-1-benzylpyrrolidin-3-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione 
• 1018814-90-8 (6S,12aR)-6-benzo[1,2,5]thiadiazol-5-yl-2-((R)-1-benzylpyrrolidin-3-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione 
• 66669-21-4 C₁₄H₁₁N₃ 
• 1024609-19-5 5-(benzo[c][1,2,5]thiadiazol-5-yl)-1-(1H-benzo[d]imidazol-5-yl)-3-hydroxy-4-(3-hydroxyphenyl)-1H-pyrrol-2(5H)-one 
• 701293-60-9 5-benzo[1,2,5]thiadiazol-5-ylmethylene-2-(2-bromophenylimino)-thiazolidin-4-one 

Relevant articles and documents

A “universal” catalyst for aerobic oxidations to synthesize (hetero)aromatic aldehydes, ketones, esters, acids, nitriles, and amides

Functionalized (hetero)aromatic compounds are indispensable chemicals widely used in basic and applied sciences. Among these, especially aromatic aldehydes, ketones, carboxylic acids, esters, nitriles, and amides represent valuable fine and bulk chemicals, which are used in chemical, pharmaceutical, agrochemical, and material industries. For their synthesis, catalytic aerobic oxidation of alcohols constitutes a green, sustainable, and cost-effective process, which should ideally make use of active and selective 3D metals. Here, we report the preparation of graphitic layers encapsulated in Co-nanoparticles by pyrolysis of cobalt-piperazine-tartaric acid complex on carbon as a most general oxidation catalyst. This unique material allows for the synthesis of simple, functionalized, and structurally diverse (hetero)aromatic aldehydes, ketones, carboxylic acids, esters, nitriles, and amides from alcohols in excellent yields in the presence of air.

NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS

The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.

Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinoline-8(4H)-one 1,1-dioxide K ATP channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent KATP opener that selectively inhibits spontaneous bladder contractions

Structure-activity relationships were investigated on a novel series of sulfonyldihydropyridine-containing KATP openers. Ring sizes, absolute stereochemistry, and aromatic substitution were evaluated for K ATP activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a select group of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation. In an anesthetized pig model of myogenic bladder overactivity, compound 14 and (-)-cromakalim 1 were found to inhibit spontaneous bladder contractions in vivo at plasma concentrations lower than those that affected hemodynamic parameters. Compound 14 showed approximately 5-fold greater selectivity than 1 in vivo and supports the concept that bladder-selective KATP channel openers may have utility in the treatment of overactive bladder.